Biosimilars Forum Welcomes Fresenius Kabi

The Forum Grows its Membership as Fresenius Kabi Joins Group

WASHINGTON, D.C. – The Biosimilars Forum welcomes Fresenius Kabi to its growing roster of member companies committed to increasing access to and adoption of biosimilars in the United States.

The Biosimilars Forum and all 10 of its member companies are committed to educating lawmakers, regulators, employers, patients and providers about the efficacy, safety and cost-saving potential of biosimilars, as well as ensuring access to these critical treatments for all who need them.

“We are thrilled to welcome Fresenius Kabi to the Biosimilars Forum,” said Juliana M. Reed, executive director of the Biosimilars Forum. “Fresenius Kabi’s commitment to providing affordable and high-quality therapies to patients mirrors our mission of increasing access and uptake of biosimilars for those who need them. The Biosimilars Forum is a voice for the industry, and we look forward to working with Fresenius Kabi to increase access to life-saving, lower-cost biosimilars.”

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition for critical and chronic conditions. In the field of biosimilars, Fresenius Kabi focuses on developing therapies in immunology and oncology.  Fresenius Kabi biosimilars are available in dozens of countries worldwide.

“Fresenius Kabisupports the Biosimilars Forum in its work to achieve commonsense, bipartisan policy to expand biosimilar access, increase competition and lower the costs for prescription drugs in America,” said Ali Ahmed, senior vice president, Biosimilars at Fresenius Kabi. “We look forward to being an active member of the Forum.”

The Biosimilars Forum is a nonprofit organization working to advance biosimilars in the United States with the goals of expanding access and availability and improving healthcare outcomes. Since its inception, the Forum has worked to expand the uptake of biosimilars throughout the healthcare system through policies that will increase access for patients and lower costs through increased competition. Forum members represent companies with the most significant U.S. biosimilars development portfolios.

For more information on the Biosimilars Forum’s work to increase access to lower cost biosimilars, visit